Phase 4 N=102 Efficacy of Multimodal Peri- and Intraarticular Drug Injections in Total Knee Arthroplasty
Osteoarthritis of the Knee
Primary: Pain at Rest (VAS) — 18; 12; 30 Units on a scale — p=0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=357 Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Disorder With Hyperactivity
Primary: Adult Attention Deficit Hyperactivity Disorder (ADHD) Investigator Symptom Rating Score (AISRS) Over Time Using the Diagnostic and Statistical Manual of Mental Disorders…
Phase 4 N=52 Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications
Acne Vulgaris
Primary: Skin Erythema (Redness) — 1.56; 1.89; 2.62; 2.65 Units on a scale — p=>0.05
Phase 4 N=90 A Study to Evaluate Tenofovir Disoproxil Fumarate (DF) in Asian-American Adults With Chronic Hepatitis B Infection
Chronic Hepatitis B
Primary: Number of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <400 Copies/mL (<69 IU/mL) — 74 Participants
Phase 4 N=232 Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection
Helicobacter Infection
Primary: Number of Participants in Which H. Pylori Was Eradicated — 92; 95 participants
Phase 4 N=123 Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder
Attention-Deficit/Hyperactivity Disorder
Primary: Percent of Treatment Failures at up to 6 Weeks — 8.9; 75.0 Percent of participants — p=<0.0001
Phase 4 N=28 Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam
Major Depressive Disorder
Primary: Midazolam Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Midazolam Alone and When Coadministered With DVS…
Phase 4 N=31 Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma
Asthma
Primary: Change (%) From Baseline in FcεRI (High-affinity IgE Receptor) Expression on Blood Basophils and Dendritic Cells After 16 Weeks of Treatment With Omalizumab as Compared…
Phase 4 N=60 The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis
Multiple Sclerosis
Primary: Percentage of Keyhole Limpet Hemocyanin (KLH) Responders at Day 28 Post-Vaccination — 89; 83 percentage of participants
Phase 4 N=233 Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)
Beta-thalassemia Major · Hemosiderosis · Iron Overload
Primary: Percentage of Participants With Treatment Success From Core Baseline (BL) to Extension End of Study, by Baseline LIC Level and Age — 75.0; 100; 72.2; 50.0 percentage of…
Phase 4 N=230 Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients
Hypertension · Type 2 Diabetes Mellitus
Primary: Change From Baseline in Mean Glycosylated Hemoglobin (HbA1c) at Week 26 — 0.12; 0.00; 0.40 Percentage
Phase 4 N=1,992 Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to < 18 Years
Influenza
Primary: Frequency and Intensity of Local and Systemic Solicited Adverse Events, Cohort A (6 Months to Less Than 3 Years) — 254; 167; 160; 111 Participants
Phase 4 N=236 A Comparison of Telemedical and Conventional Antihypertensive Treatment
Hypertension
Primary: Difference in Number of Patients Who Reached Target Blood Pressure
Phase 4 N=76 Outcomes of Anterior Colporrhaphy Versus Graft Reinforced Anterior Prolapse Repair
Cystocele · Uterine Prolapse · Urinary Incontinence
Primary: Recurrent Stage II or Greater Anterior Vaginal Prolapse — 24; 11 participants — p=0.005
Phase 4 N=48 Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers
Bacterial Infections · Eye Infections
Primary: Assessment of Pharmacokinetic Parameters